Testing Simeox for severe COPD with lung hyperinflation
Part of Lungs & breathing clinical trials.
This trial tests if a device called Simeox can reduce trapped air in the lungs of people with severe COPD. It may help you breathe easier if you have pulmonary hyperinflation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have severe or very severe COPD (GOLD stage 3 or 4)
- You must have documented lung hyperinflation (higher trapped air than normal)
- You must be stable (no flare-ups in the last 3 weeks)
- You cannot have recent lung collapse, active bleeding in the lungs, unstable heart problems, or serious muscle weakness
- You must be able to give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device that briefly opens your airways to help release trapped air after exercise. It may reduce shortness of breath and improve your daily life with COPD.
This trial tests whether a device that helps you breathe during exercise can improve how long you can keep going. It aims to help people with severe COPD who have too much carbon dioxide in their blood or who get easily exhausted.
This trial tests whether a new device called Simeox works better than standard chest physical therapy for people with bronchiectasis (widened airways that trap mucus). It compares how well each method clears mucus from the lungs.
This study tests a device called Simeox to help people with bronchiectasis clear mucus from their lungs more easily. It may be an option if you have a daily cough with mucus and are already using airway clearance therapy.
This study tests a home-use device called SIMEOX, which helps clear mucus from your lungs. It is for adults with bronchiectasis (not cystic fibrosis) who have frequent lung infections.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.